Valeant Pharmaceuticals’ Branded Rx Products after 4Q17


Apr. 6 2018, Updated 1:20 p.m. ET

Apriso and Glumetza: Revenue trends

In 4Q17, Valeant Pharmaceuticals International’s (VRX) Apriso generated revenues of $34 million compared to $39 million in 4Q16. That was a 13% decline on a YoY (year-over-year) basis and a 19% decline quarter-over-quarter. In fiscal 2017, Apriso reported revenues of $144 million.

Apriso (mesalamine) is used for the maintenance of remission of ulcerative colitis. Some other drugs used for the treatment of ulcerative colitis include Novartis’s (NVS) Neoral, Pfizer’s (PFE) Azulfidine, and Takeda Pharmaceuticals’ (TKPYY) Entyvio.

In 4Q17, Glumetza reported revenues of $27 million compared to $24 million in 4Q16, which reflected a 13% growth on a YoY basis and a 41% decline quarter-over-quarter. In 2017, Glumetza generated net revenues of $133 million.

Glumetza (metformin hydrochloride) is used for the treatment of diabetes mellitus.

Article continues below advertisement

Uceris and Arestin: Revenue trends

In 4Q17, Uceris tablets reported revenues of $37 million, a 16% YoY decline. In 4Q17, Uceris’s quarter-over-quarter revenues remained flat.

In 4Q17, Arestin reported revenues of $33 million, which was an 11% YoY decline and a 27% YoY growth.

In 2017, Uceris and Arestin generated revenues of $140 million and $111 million, respectively.

Uceris (budesonide) is used for the induction of remission in individuals with active, mild-to-moderate ulcerative colitis.

Retin-A franchise: Revenue trends

In 4Q17, the Retin-A franchise reported revenues of $20 million, a 38% YoY decline and a 26% decline quarter-over-quarter. In 2017, it generated revenues of $102 million.

Elidel, Solodyn, and Relistor: Revenue trends

In 4Q17, Elidel generated revenues of $24 million, a 4% YoY growth and a 14% quarter-over-quarter growth. Elidel is used for the treatment of eczema.

In 4Q17, Solodyn reported revenues of $10 million, a 66% YoY decline and a 29% quarter-over-quarter decline. Solodyne is used use for the treatment of acne.

In 4Q17, Relistor generated revenues of $25 million, a 67% YoY growth and a 47% quarter-over-quarter growth. Relistor is used for the treatment of constipation due to the use of opioids.

In fiscal 2017, Elidel, Solodyn, and Relistor reported revenues of $84 million, $71 million, and $69 million, respectively.


More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market RealistLogo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.